Leadless ICD Endovascular Placement Technology 2026
Leadless ICD Endovascular Placement Technology 2026
Transvenous lead complications—including infection rates driving 55–74% of all extraction procedures—are propelling the field toward leadless intracardiac and extravascular defibrillation architectures. This dataset spans four structurally distinct non-transvenous ICD approaches across commercial platforms.
Four Structural Approaches to Non-Transvenous ICD Therapy
The technology field documented in this dataset spans four distinct approaches that avoid traditional transvenous endovascular lead placement: leadless intracardiac right ventricular pacemakers, subcutaneous ICD systems, extravascular ICD systems with substernal or intercostal lead placement, and wireless endocardial left ventricular stimulation platforms such as the WiSE-CRT system by EBR Systems.
The foundational clinical problem motivating all four approaches is well-quantified in retrieved records. Transvenous lead extraction registries document major complication rates of approximately 3.57% and in-hospital mortality of 2.27% in infected device populations, while lead dislodgement and phrenic nerve stimulation collectively affect 15–36% of patients depending on lead configuration.
The Micra Transcatheter Pacing System (Medtronic) represents the dominant leadless intracardiac pacemaker platform in this dataset, anchored with nitinol tines via a transfemoral catheter approach. In a 6,219-patient vs. 10,212-patient Micra CED Medicare registry analysis published in 2021, Micra demonstrated reduced reintervention rates at 2 years compared to transvenous VVI pacing.
In retrieved records, Medtronic appears as the most prominent assignee, spanning Micra TPS and EV-ICD substernal platform development. EBR Systems holds the WiSE-CRT wireless endocardial LV pacing platform, and AtaCor Medical holds the intercostal EV-ICD lead approach in this dataset. Boston Scientific appears via S-ICD platform references.
Platform Performance and Complication Profiles Across Retrieved Records
Retrieved clinical records document quantified outcome differentials between transvenous and non-transvenous device approaches, providing a comparative evidence base for platform assessment across pacing and defibrillation modalities.
Complication Rates: Transvenous vs. Leadless Approaches (Retrieved Records)
In this dataset, Micra leadless pacemaker shows a pooled 90-day complication incidence of 0.46% and 51% lower odds of complications at 1 year versus transvenous VVI, while transvenous lead extraction carries a 3.57% major complication rate in infected-device populations.
↗ Click bars to exploreInnovation Timeline: Key Milestones by Period (Dataset Snapshot)
In this dataset, the 2017–2020 period accounts for the highest density of real-world registry publications, followed by the 2021–2023 period which introduced EV-ICD pivotal studies, LOT-ICD concepts, and complex anatomy first-in-human reports.
↗ Click bars to exploreKey Clinical Application Domains for Non-Transvenous ICD Technology
Retrieved clinical records document five distinct patient populations driving adoption of leadless and extravascular ICD technologies, each characterized by specific anatomical or infectious contraindications to conventional transvenous device systems.
Recurrent CIED Infection Patients
Device-related infection accounts for 55–74% of all transvenous lead extraction indications across TLE registry studies in retrieved records. The ESC-EHRA ELECTRa registry enrolled 3,555 patients across 73 centers in 19 countries documenting extraction outcomes. Leadless pacemaker implantation as an infection-avoidance strategy after conventional CIED pocket infection was documented as early as 2016 in a US case series.
Infection AvoidanceHeart Failure CRT Non-Responders
The WiCS-LV Post Market Surveillance Registry enrolled 90 patients across 14 European centers as of 2020, with mean LVEF 30.6% and mean QRS 180.7 ms—predominantly patients who failed or were ineligible for transvenous CRT. Eight patients received the totally leadless CRT system combining Micra plus WiSE-CRT, achieving acute QRS reduction in all 8. EBR Systems is the sole platform assignee documented in this dataset.
Leadless CRT DeliveryCongenital Heart Disease Complex Anatomy
Multiple case reports in retrieved records document leadless pacemaker implantation in congenitally corrected transposition of the great arteries, univentricular hearts, persistent left superior vena cava, and patients with mechanical tricuspid valves. A 2022 first-in-human report documented simultaneous transcatheter tricuspid valve implantation with leadless VDD pacemaker via left internal jugular approach. A 2018 case documented successful Micra implantation via collateral femoral vein and inferior vena cava filter.
Non-Standard AnatomyTranscatheter Valve and LVAD Patients
A single-center 2022 US study compared 27 leadless pacemaker vs. 33 dual-chamber pacemaker patients post-TAVI, finding no significant differences in device usage or ejection fraction at 1 year. In a 537-patient multicenter LVAD cohort, 13% of CRT-D patients experienced device-related complications over median 538-day follow-up, establishing the clinical case for non-transvenous alternatives in this population.
Structural Heart IntegrationKey Patent and Clinical Assignees in Leadless ICD Technology — Dataset Snapshot
In this dataset, three commercial assignees account for essentially all platform-level development activity in ICD-capable non-transvenous systems: Medtronic, EBR Systems, and AtaCor Medical. Medtronic appears across at least 8–10 distinct studies in retrieved records spanning both the Micra TPS and EV-ICD substernal programs.
Platform Assignees by Study Presence in Retrieved Records (Dataset Snapshot)
↗ Click bars to exploreMedtronic
Medtronic appears across at least 8–10 distinct studies in this dataset spanning 2015–2022, covering the Micra Transcatheter Pacing System and the EV-ICD substernal lead program. The Micra CED study drew from US Medicare claims data (6,219 Micra vs. 10,212 transvenous VVI patients), and the EV-ICD pivotal study enrolled up to 400 patients globally with 3.5-year follow-up. The extravascular ICD development program summarized preclinical and 4 human clinical studies with over 140 combined implants.
United StatesEBR Systems
EBR Systems (Sunnyvale, CA) is the sole assignee for the WiSE-CRT wireless endocardial LV pacing platform in this dataset, with clinical data concentrated in 14 European centers as of the 2020 WiCS-LV Post Market Surveillance Registry (90 patients). The system delivers ultrasound-powered endocardial LV pacing via a miniaturized electrode implanted in the LV endocardium, synchronized to a right ventricular pacemaker signal. The totally leadless CRT system combining Micra and WiSE-CRT was first demonstrated in 8 European patients in 2020.
United States — CAFive Forward-Looking Signals in Leadless and Extravascular ICD Development
The most recent publications and feasibility reports in this dataset (2021–2023) identify five directional signals pointing toward fully integrated leadless CRT-D systems, extravascular ICD commercialization, and conduction system pacing as a disruptive CRT-D modality.
Fully Leadless CRT-D Three-Component Systems
The combination of Micra (RV pacing), WiSE-CRT (wireless LV endocardial pacing), and an S-ICD represents a conceptually complete three-component leadless CRT-defibrillator system. A 2021 publication explicitly addresses the system-level engineering challenge of leadless pacemaker positioning relative to S-ICD sensing template. Eight European patients received the Micra plus WiSE-CRT totally leadless CRT configuration in 2020, achieving acute QRS reduction in all 8.
EV-ICD Substernal and Intercostal Pivotal Studies
Medtronic’s EV-ICD substernal platform entered a worldwide pivotal study enrolling up to 400 patients with Class I or IIa ICD indication and up to 3.5-year follow-up, with primary endpoint publication windows anticipated approximately 2025–2026. AtaCor Medical’s 2023 intercostal EV-ICD approach using DF-4-compatible commercial pulse generators in 36 patients introduces a distinct anatomical access strategy that may lower adoption barriers. Both approaches provide defibrillation and pacing capability without transvenous lead risks.
Leadless/Extravascular ICD Architectures: Head-to-Head Comparison
Click any row to explore further.
| Dimension | Micra TPS + S-ICD (Leadless RV + Subcutaneous ICD) | EV-ICD Substernal System (Medtronic) |
|---|---|---|
| Lead Location | Micra anchored within right ventricle via nitinol tines; S-ICD shock coil subcutaneous parasternal/lateral thoracic | Lead placed in substernal space between sternum and pericardium; outside vasculature but closer to heart than S-ICD |
| Pacing Capability | RV single-chamber pacing via Micra; no transvenous pacing lead; S-ICD provides defibrillation only | Provides both defibrillation and anti-tachycardia pacing without transvenous lead risks |
| Delivery Approach | Micra delivered via transfemoral catheter; S-ICD via parasternal subcutaneous pocket approach | Substernal dissection approach; generator positioned in pectoral or axillary pocket |
| Clinical Evidence Stage | First-in-human combined system 2015; multi-center European registry data; 2021 S-ICD sensing interaction study | Preclinical plus 4 human clinical studies with over 140 combined implants as of 2022; pivotal study enrolling up to 400 patients |
| Primary Assignee | Medtronic (Micra); Boston Scientific (S-ICD) | Medtronic EV ICD Program |
| Key Differentiator | Three-component leadless CRT-D possible with WiSE-CRT addition; electromagnetic interaction characterized in 2022 study | Anti-tachycardia pacing capability is key differentiator versus S-ICD; DF-4 compatible intercostal variant by AtaCor Medical (2023) |
| Patient Population | Complex anatomy, prior infection, congenital heart disease, TAVI patients documented in retrieved case series | Class I or IIa ICD indication patients enrolled in pivotal study; infection-avoidance and anti-pacing needs |
Frequently Asked Questions: Leadless ICD Endovascular Placement Technology
The four approaches are: (1) leadless intracardiac right ventricular pacemakers such as the Micra TPS delivered via femoral vein transcatheter approach; (2) subcutaneous ICD systems positioned entirely outside the vasculature with parasternal or lateral thoracic lead configuration; (3) extravascular ICD systems with substernal or intercostal lead placement providing defibrillation and anti-tachycardia pacing; and (4) wireless endocardial LV stimulation platforms such as the WiSE-CRT system by EBR Systems delivering ultrasound-powered endocardial pacing.
Transvenous lead extraction registries in retrieved records document major complication rates of approximately 3.57% and in-hospital mortality rates of 2.27% in infected device populations. Lead dislodgement and phrenic nerve stimulation collectively affect 15–36% of patients depending on lead configuration. Device-related infection accounts for 55–74% of all extraction indications across TLE registry studies.
The WiSE-CRT system by EBR Systems delivers ultrasound-powered endocardial LV pacing via a miniaturized electrode implanted in the LV endocardium, synchronized to a right ventricular pacemaker signal. It targets patients with heart failure who have failed or are ineligible for transvenous CRT. The WiCS-LV registry enrolled 90 patients across 14 European centers with mean LVEF 30.6% and mean QRS 180.7 ms.
LOT-ICD (left bundle branch pacing-optimized ICD) uses a deep septal Medtronic 3830 Selectsecure lead connected at the RV-P/S port of a dual-chamber ICD generator, achieving physiologic ventricular synchronization via left bundle branch pacing and eliminating coronary sinus LV lead placement entirely. A 2022 pilot study demonstrated stable R-wave sensing for arrhythmia monitoring with reduced fluoroscopy compared to conventional CRT-D configurations.
According to retrieved records, the EV-ICD pivotal study plan describes enrollment of up to 400 patients with Class I or IIa ICD indication, with up to 3.5-year follow-up, comparing the EV-ICD substernal system against transvenous ICD benchmarks. The program summarized preclinical and 4 human clinical studies with over 140 combined implants as of the 2022 development summary publication.
Retrieved case reports document leadless pacemaker implantation in patients with congenitally corrected transposition of the great arteries, univentricular hearts, persistent left superior vena cava, mechanical tricuspid valves, and patients requiring IVC filter traversal or collateral femoral vein access. A 2022 first-in-human report documented simultaneous transcatheter tricuspid valve implantation with a leadless VDD pacemaker via the left internal jugular approach.
Data and insights on this page are based on a limited patent and literature dataset and are for reference only. Figures may not represent the complete technology landscape.